|1.||Canafax, Daniel: 1 article (11/2010)|
|2.||Druzgala, Pascal: 1 article (11/2010)|
|3.||Weitz, Jeffrey I: 1 article (11/2010)|
|4.||Bowersox, S Scott: 1 article (11/2010)|
|5.||Milner, Peter: 1 article (11/2010)|
|6.||Milner, Peter G: 1 article (09/2009)|
|7.||Ellis, David J: 1 article (09/2009)|
|8.||Ezekowitz, Michael D: 1 article (09/2009)|
|9.||Usman, Mohammed Haris: 1 article (09/2009)|
|10.||Canafax, Daniel M: 1 article (09/2009)|
09/22/2009 - "This is the first study of tecarfarin in patients with atrial fibrillation. "
09/22/2009 - "This was a 6- to 12-week open-label, multicenter, phase IIA study of 66 atrial fibrillation patients with a mild to moderate risk of stroke to determine the safety and tolerability of tecarfarin and to ascertain an optimal tecarfarin dosing regimen. "
09/22/2009 - "The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation."
11/01/2010 - "A 4 to 7day course of oral tecarfarin (0.05 - 0.5mg/kg) prolonged the PT by 3 to 5-fold and reduced thrombus formation in arterial and venous segments subjected to a combination of electrical injury and flow-limiting constriction. "
11/01/2010 - "Compared with the saline control, both tecarfarin and warfarin prolonged the PT, increased blood loss from the ear incisions, and attenuated thrombus formation. "
11/01/2010 - "The antithrombotic activity of tecarfarin, a novel orally active vitamin K epoxide reductase inhibitor, was assessed in canine and rabbit thrombosis models. "
11/01/2010 - "Thus, like warfarin, tecarfarin attenuates venous and arterial thrombus formation in animal models by reducing the levels of the vitamin K-dependent coagulation factors."
|3.||Blood Coagulation Factors (Coagulation Factor)
|4.||vitamin K epoxidase (vitamin K epoxide reductase)